Genentech Omaspect GX30191 EXT

Status: Roll-over study, not opened for enrollment

GX30191: A multi-center, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with GA secondary to AMD who have completed a Roche-Sponsored Study

Condition: Geographic Atrophy

Study Type: Interventional

Duration: 96 weeks

Eligibility:

  • Previous enrollment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531) with completion of treatment and the Week 96 visit
  • Ages: Child, Adult, Senior
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.